Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: Do the Dead Cats Bounce?

(Image via CGX Energy Inc.) You’ve heard that what goes up must come down, but in the stock trading world, what goes down should come up. Even a dead cat can bounce if it falls from high enough up, right? The markets coined this term believing th...
Stockhouse Editorial | May 11, 2022 |

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke

(CLICK IMAGE TO PLAY VIDEO) Finding an effective method of preventing the possibility of stroke is something that medical science has grappled with for decades. Now, a Vancouver-based clinical stage biopharmaceutical development company looks to be making significa...
Dave Jackson | June 16, 2021 |

Buzz on the Bullboards: Who benefits from the latest stock market rally?

It was a more nuanced performance for stock markets in Toronto and New York this week with notable gains and splits between indices capturing investor attention. The TSX surged to highs not seen in a month, buoyed by optimism, while in the United States, some stocks ...
Jonathon Brown | May 9, 2024 |

Medicus Pharma advances cancer treatment towards phase II trial

The following is a transcription of the above video, and The Market Herald Canada has edited it for clarity . Our next company is Medicus Pharma Ltd. (TSXV:MDCX) , headquartered in Philadelphia, Pennsylvania. The company is a publicly traded clinical stage, multi-st...
Ryan Dhillon | January 22, 2024 |

Edesa Shares Double Upon Gaining Approval to Initiate Phase 2/3 COVID-19 Study

Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19. Clinical-stage biopharmaceutical company Edesa B...
Streetwise Reports | June 16, 2020 |

Flying Under the Radar with a Possible COVID-19 Treatment

Investors would think a pharmaceutical company heading into Phase 2b/3 human trials for treating the third most malignant disease after lung cancer and pancreatic cancer would draw eyes from major players. If that same company announced it was embarking on Phase2b/3 human tri...
Stockhouse Editorial | September 8, 2020 |

Coronavirus Propels Telemedicine into the Spotlight

Summary: Coronavirus could be the game changer that propels telemedicine into the mainstream. Virtual clinical services have been around since the '90s but had failed to catch on. Now, a concerted effort by healthcare providers, insurance companies, the federal government...
Streetwise Reports | March 27, 2020 |

Why This Psychedelics Company is Focused on Weight Management

Psychedelics are transforming so many aspects of our everyday lives — from treating mental health conditions to weight management and obesity. Companies like NeonMind Biosciences ( CSE:NEON , OTCQB:NMDBD , Forum ) are at the forefront of this innovation ...
Jocelyn Aspa | May 4, 2022 |

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'

The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. In a March 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Nabriva Therapeutics Plc (NBRV:NASDAQ) has two antibiotics up for approval...
Streetwise Reports | March 21, 2019 |

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |
1 2 3 4 5 6 7 8 9 10 ...